What question did this study set out to answer?

To review the pharmacological mechanisms, antithrombotic efficacy, and safety profile of dermatan sulphate and related compounds across clinical settings.

January 1, 2002Pathophysiology of Haemostasis and ThrombosisOpen Access

Dermatan Sulphate as an Antithrombotic Drug

View Full Paper

Ask AI

Bookmark

Why the study?

Is dermatan sulphate effective and safe for thromboprophylaxis and anticoagulation compared to heparin?

Population

Patients requiring thromboprophylaxis, hemodialysis, or treatment for venous and arterial leg diseases

Comparison

Dermatan sulphate, low-molecular-weight DS, and… vs Heparin

Design

Review

Authors

GNGiuseppe G. NenciUniversity of Perugia

Discussion

Member takes

Implication

May support evaluation in oncological surgery; leaves open randomized confirmation versus heparin.

Key Points

To review the pharmacological mechanisms, antithrombotic efficacy, and safety profile of dermatan sulphate and related compounds across clinical settings.
Synthesized findings from clinical thromboprophylaxis trials in medical patients and those undergoing general, orthopedic, and oncological surgery.
Evaluated comparative trials of dermatan sulphate versus heparin in hemodialysis and pilot investigations of low-molecular-weight formulations for venous thromboembolism.
Assessed clinical study outcomes for dermatan sulphate-containing compounds, specifically sulodexide and mesoglycan, in peripheral vascular disorders.
Dermatan sulphate selectively inactivated thrombin through Heparin Cofactor II without interacting with Antithrombin III, retaining activity against fibrin-bound thrombin.
Dermatan sulphate demonstrated superior prophylactic efficacy compared to heparin in oncological surgery without excess bleeding, while showing no statistically significant differences in hemodialysis.
Formulations including low-molecular-weight dermatan sulphate, sulodexide, and mesoglycan showed therapeutic effectiveness for venous thromboembolism and leg vascular diseases.

Structured PICO

Is dermatan sulphate effective and safe for thromboprophylaxis and anticoagulation compared to heparin?

Population

Patients requiring thromboprophylaxis (medical, general, orthopedic, and oncological surgery), hemodialysis, or treatment for venous and arterial leg diseases

Intervention

Dermatan sulphate (DS), low-molecular-weight DS, and DS-containing compounds (sulodexide, mesoglycan)

Comparator

Heparin

Outcome

Efficacy and safety (thromboprophylaxis, anticoagulation, and bleeding risk)

Dermatan sulphate is a promising antithrombotic agent that may offer efficacy superior or comparable to heparin in specific clinical settings without increasing bleeding risk.

Cite This Study

Giuseppe G. Nenci (2002) studied this question.

synapsesocial.com/papers/6a77d7bfd8eb58afc2be2ce7 https://doi.org/10.1159/000073586

View Full Paper

Ask AI

Bookmark

Dermatan Sulphate as an Antithrombotic Drug

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Dermatan Sulphate as an Antithrombotic Drug

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider